Array Biopharma (ARRY) Misses Q1 EPS by 4c, Sales Beat

November 1, 2016 8:02 AM EDT
Get Alerts ARRY Hot Sheet
Trade ARRY Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Array Biopharma (NASDAQ: ARRY) reported Q1 EPS of ($0.20), $0.04 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $39.3 million versus the consensus estimate of $32.47 million.

"We were pleased to report that COLUMBUS met its primary endpoint and demonstrated a robust PFS benefit associated with the combination of binimetinib plus encorafenib versus vemurafenib in patients with BRAF-mutant melanoma," said Ron Squarer, Chief Executive Officer of Array BioPharma. "We look forward to sharing results at SMR, partnering with global regulatory authorities on planned 2017 submissions for COLUMBUS and preparing for potential commercialization."

For earnings history and earnings-related data on Array Biopharma (ARRY) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Earnings, Management Comments

Related Entities


Add Your Comment